Anaptysbio Inc (ANAB) Return on Investment ROI from the first quarter of 2026 to first quarter of 2025 and for the year 2026, average high and low, overall ranking from Mar 31 2026 to Mar 31 2025 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Anaptysbio Inc   (NASDAQ: ANAB)


Anaptysbio Inc's ROI from its first quarter of 2026 to the first quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Anaptysbio Inc's ROI in the first quarter of 2026?
Due to the stockholders deficit and subsequent negative measured investments, it was not possible to calculate Anaptysbio Inc 's return on investment (ROI) in its first quarter of 2026

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter
Y / Y Investment Change TTM - - -86.64 % -45.7 % -50.8 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 13 37 -29 -45 34
Return On Investment (TTM) 442.91 % 1813.85 % - - -282.47 %
ANAB's Overall Ranking # # # # #
Seq. Investment Change TTM - - -78.73 % -27.42 % -6.46 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -27 -13 -85 -133 -141

ANAB Company Profile >> Back to ANAB Roi Comparisons >> See Annual ANAB Return On Investment



Return On Investment ANAB's Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Investment Statistics
High Average Low
0 %
0 %
0 %
 



  News about Anaptysbio Inc Return on Investment ROI

Anaptys Biosciences Announces Successful Completion of $100 Million Underwritten Registered Direct Offering, Fueling Growth Momentum

August 14, 2024



San Diego-based clinical-stage biotechnology company, Anaptys Biosciences, has recently announced the successful completion of a $100 million underwritten registered direct offering. This landmark transaction was led by long-standing investor EcoR1 Capital, with notable participation from additional existing and new investors, including pharmaceutical giant Sanofi. As a result of this significant funding infusion, Anaptys aims to enhance its research and development efforts and provide a strong foundation for future growth.
The strategic collaboration with leading investors underscores the industry s recognition of Anaptys Biosciences innovative drug development programs and potential. With the newfound capital, the company is poised to accelerate the clinical advancement of its robust pipeline, focused on creating novel antibody therapeutics targeting severe inflammatory diseases and immuno-oncology indications.





Financial Statements
Anaptysbio Inc's I. Quarter Investments $ 13 Millions ANAB's Balance sheet
Anaptysbio Inc's I. Quarter Income $ -53 Millions Quarterly ANAB's Income Statement
ANAB's Income by Division See ANAB's Income by Division


ANAB Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 37 71 88 262 627
Y / Y Investment Growth -47.49 % -19.56 % -66.39 % -58.2 % 58.03 %
Net Income in Millions -13 -145 -164 -129 -58
Y / Y Net Income Growth - - - - -
Annual Return On Investment -35.56 % -204.93 % -185.71 % -49.11 % -9.22 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
ANAB's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for ANAB's Competitors
Subscribers only: Roi for Anaptysbio Inc's Suppliers
Subscribers only: Return On Investment for ANAB's Customers

Other Ratios
ANAB's Roa ANAB's Inventory Turnover Ratio ANAB's Growth Rates ANAB's Dividend Statistics
ANAB's Profitability Ratios ANAB's Asset Turnover Ratio ANAB's Dividend Growth
ANAB's Roe ANAB's Valuation Ratios ANAB's Financial Strength Ratios ANAB's Dividend Payout Ratio



Companies with similar Return On Investment at Mar 31 2026, within Healthcare Sector ROI
Stablecoin Development Corporation  1,098.22 %
Glucotrack Inc   537.70 %
Sanuwave Health Inc   313.81 %
Elutia Inc   232.45 %
Silexion Therapeutics Corp  206.92 %
Kyntra Bio Inc   155.01 %
Rigel Pharmaceuticals Inc  132.72 %
Interpace Biosciences Inc   130.15 %
Oncotelic Therapeutics Inc   129.74 %
Coherus Oncology inc   128.80 %
Petros Pharmaceuticals inc   124.23 %
Arbutus Biopharma Corp  119.86 %
Quince Therapeutics Inc   114.14 %
Capforce Inc   102.27 %

Date modified: 2026-09-18T13:11:06+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.